A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Heart Failure
Interventions
DRUG

Finerenone

Oral finerenone.

DRUG

Empagliflozin

Oral empagliflozin.

Trial Locations (15)

30303

RECRUITING

CON-10022 Atlanta, GA Investigational Site, Atlanta

36532

RECRUITING

CON-10004 Fairhope, AL Investigational Site, Fairhope

64111

RECRUITING

CON-10002 Kansas City, MO Investigative Site, Kansas City

70808

RECRUITING

CON-10030 Baton Rouge, LA Investigational Site, Baton Rouge

78705

RECRUITING

CON-10015 Austin, TX Investigational Site, Austin

79106

RECRUITING

CON-10045 Amarillo, TX Investigational Site, Amarillo

92243

RECRUITING

CON-10075 El Centro, CA Investigational Site, El Centro

95816

RECRUITING

CON-10024 Sacramento, CA Investigational Site, Sacramento

12916542

RECRUITING

CON-21004 Braganca Paulista, Sao Paulo Investigational Site, Bragança Paulista

74453-200

RECRUITING

CON-21003 Goiania, Goias Investigational Site, Goiânia

89200-000

RECRUITING

CON-21007 Joinville, Santa Catarina Investigational Site, Joinville

05652-900

RECRUITING

CON-21049 Sao Paulo, Sao Paulo Investigational Site, São Paulo

V3V OC6

RECRUITING

CON-11012 Surry, BC Investigational Site, Surrey

M6B 3H7

RECRUITING

CON-11007 North York, ON Investigational Site, North York

J1H 5N4

RECRUITING

CON-11005 Sherbrooke, QC Investigational Site, Sherbrooke

All Listed Sponsors
collaborator

Saint Luke's Mid America Heart Institute

UNKNOWN

collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

Colorado Prevention Center

OTHER